Shattering Myths FDA New Era of Diverse Healthcare Solutions
In an era marked by rapid advancements in healthcare, the importance of inclusivity and innovation in clinical trials and...
Pfizer Bold 2024 Forecast: A New Era Dawns
Pfizer Inc. has provided its financial forecast guidance for the full year of 2024, accounting for the anticipated impact...
ACRO Unveils Power Squad for 2024: Meet the New Faces
The Association of Clinical Research Organizations (ACRO) announced the election of Peyton Howell, Chief Operating & Growth Officer at...
Miracle CAR T-Cell Hope from Gilead for Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), has presented encouraging data from various studies on the CAR T-cell therapies Tecartus®...
Mooresville Locals Breathe Easy with Sanofi COPD Study
A new clinical trial, known as the AERIFY-2 study, is underway in Mooresville, N.C., focusing on chronic obstructive pulmonary...
Pfizer & Seagen Merge: A Monumental, Surprising Union
Pfizer Inc. has reached a significant milestone in its pending acquisition of Seagen Inc., with all required regulatory approvals...
Metasite Mastery: Science 37 DCT Breakthrough
This interview features the innovative world of decentralized clinical trials (DCTs) with insights from Darcy Forman of Science 37....
Merck & Moderna Blaze Trail with New Cancer Vaccine Trial
Merck, and Moderna, Inc., have launched INTerpath-002, a pivotal Phase 3 randomized clinical trial for a cancer vaccine. The...
Sanofi Venetoclax: Breakthrough NK Cell Therapy Stuns at ASH 2023
Innate Pharma SA, in collaboration with Sanofi, shared updated efficacy and safety results from a Phase 1/2 dose-escalation study...
Merck, Eisai’s Shock: KEYTRUDA-LENVIMA Fail
Merck and Eisai have reported that the Phase 3 LEAP-001 trial for the first-line treatment of patients with advanced...